Literature DB >> 9437272

Diabetes drug withdrawn after reports of hepatic events.

J Wise.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9437272      PMCID： PMC2128004          DOI： 10.1136/bmj.315.7122.1559n

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

Review 1.  Hepatotoxicity with thiazolidinediones: is it a class effect?

Authors:  A J Scheen
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Drug treatment of hypertension complicating diabetes mellitus.

Authors:  M J MacLeod; J McLay
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

3.  Monitoring the safety of pioglitazone : results of a prescription-event monitoring study of 12,772 patients in England.

Authors:  Rachna Kasliwal; Lynda V Wilton; Saad A W Shakir
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

4.  Risk management and outcomes of adverse events to pioglitazone in primary care in the UK: an observational study.

Authors:  Carole Fogg; Rachna Kasliwal; Saad A W Shakir
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 5.  Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges.

Authors:  John R Senior
Journal:  Drug Saf       Date:  2014-11       Impact factor: 5.606
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.